Regeneron’s AAV gene therapy for congenital deafness has been approved by the FDA — a clinical victory for helping patients and an exciting milestone for gene therapy in general!

Approved Thursday via the FDA’s Commissioner’s National Priority Voucher program, Otarmeni is the first gene therapy for hearing loss—and the first treatment to target an underlying cause of the condition.